Overview and Procedural Posture
In an appeal under Section 117A of the Patents Act, 1970, the Delhi High Court upheld the Controller's rejection (order dated 27 April 2023) of Patent Application No. 201817033732, titled "Organic Compounds," covering deuterated heterocycle-fused gamma-carboline compounds (Formulas I–IV) with applications in treating schizophrenia, psychosis, anxiety, sleep disorders, and related conditions. The Controller had rejected the claims on three grounds: lack of novelty (Section 2(1)(j)), obviousness (Section 2(1)(ja)), and non-patentability under Section 3(d). Having sustained the novelty and Section 3(d) findings, the Court found it unnecessary to separately decide inventive step.
The Controller's Reasoning
On novelty: the Controller treated prior art documents D1 and D7 as anticipating different claim clusters — D1 for the Formula IV claims, D7 for the Formula I–III claims — holding that specific selections from each document's generic disclosure resulted directly in the claimed compounds.
On inventive step: the Controller's reasoning was that D4–D6 disclosed the general "principle of using deuterated alternatives of known drugs," and since this principle could be applied to the base compounds in D1/D7, the claimed deuterated compounds were obvious — without independently analysing each claim cluster or articulating what would motivate a skilled person to select the specific deuteration positions claimed.
On Section 3(d): the Controller held the claims "not allowable," reasoning that the compounds "are same as disclosed in D1 & D7" — a conclusion textually derived from the novelty finding rather than an independent efficacy analysis, and made with no reference anywhere to the co-inventor's affidavit filed three separate times during prosecution.
The Appellant's Case
Intra-Cellular raised several substantial objections. On procedure, it noted the novelty objection appeared only at the second hearing notice, suggesting it was an afterthought. On novelty, it argued the invention was a species patent requiring "multiple independent selections" from the generic Formula I of D1/D7, that settled practice requires a single document as closest prior art (not multiple documents treated collectively), and — tellingly — that the EPO's Search Opinion, examining the identical D1–D7 documents, had found the claims novel. It also relied on subsequent research showing the specific deuteration positions claimed produced metabolic benefits that positions disclosed in D7 did not.
On inventive step, the appellant argued the Controller's reasoning was "cryptic and unreasoned," never explaining how or why a skilled person would combine D1/D7 with D4–D6, relying on F. Hoffmann-La Roche Ltd. v. Cipla Ltd. and Agriboard International LLC v. Deputy Controller of Patents for the requirement that obviousness reasoning must articulate a motivation to combine.
On Section 3(d), the appellant argued the "known substance" was never identified in either hearing notice, relying on Taiho Pharmaceutical Co. Ltd. v. Controller of Patents's three-factor test, and pointed to experimental data (Examples 5–7 of the specification) showing significantly different metabolic profiles for the deuterated compounds — data the Controller never addressed.
On the co-inventor's affidavit (Dr. Peng Li's, filed three times during prosecution), the appellant argued its complete non-consideration violated Milliken and Company v. Controller of Patents and The Regents of the University of California v. Union of India, both holding that a Controller's failure to consider material evidence on record vitiates the order.
The Respondent's Case
The Controller defended the mapping of D1 and D7 to their respective claim clusters, and — notably — argued that because Intra-Cellular was itself the applicant behind the prior art documents D1 and D7, anticipation should be tested not against the ordinary "person skilled in the art" but against the heightened "person in the know" standard, relying on AstraZeneca AB v. Intas Pharmaceuticals Ltd. On Section 3(d), the Controller argued the pharmacokinetic data relied upon showed only better exposure/metabolic performance, not enhanced therapeutic efficacy, per Novartis AG v. Union of India. On the foreign grants point, the Controller invoked territoriality: Indian patentability is governed solely by the Patents Act, and foreign grants (including the EPO's) are not binding.
The Court's Findings
Novelty: the Court accepted the Controller's mapping and rejected the "multiple selections" argument, holding it a settled position that where a compound is covered by a genus patent's claims, specific disclosure is immaterial — grounded in AstraZeneca AB and Boehringer Ingelheim Pharma GMBH v. Vee Excel Drugs, which treat "claimed," "covered," "encompassed," and "disclosed" as functionally equivalent for anticipation purposes.
Section 3(d): the Court reiterated that "efficacy" means strictly therapeutic efficacy, not mere pharmacokinetic improvement. It independently identified compound Q (from D1/D7) as the "known substance," then examined the appellant's own dog pharmacokinetic data (72% higher parent-drug AUC) and the co-inventor's affidavit, holding that enhanced bioavailability does not, by itself, establish enhanced therapeutic efficacy — relying on Natco Pharma v. Novartis AG (Division Bench), which held bioavailability is "one of the pharmacokinetic parameters and not a direct measure of therapeutic efficacy."
The co-inventor's affidavit: rather than remanding for the Controller's silence on it, the Court examined the affidavit's contents itself on appeal, found the data duplicative of material already assessed, and held the natural-justice precedents cited by the appellant "need not be looked into" — treating the appellate court's own substantive assessment as curing any first-instance defect.
Inventive step: having upheld both novelty and Section 3(d), the Court held it "does not feel the requirement to address" the inventive step objection, leaving the appellant's detailed submissions on that ground unaddressed on the merits.
Foreign grants: the Court did not substantively engage the appellant's point that the EPO, examining the identical D1–D7 prior art, reached the opposite novelty conclusion — the point was subsumed within the territoriality principle without comparative analysis of the EPO's selection-invention framework.
Summary Table
| Issue | Appellant | Respondent | Court's Finding |
|---|---|---|---|
| Novelty (S. 2(1)(j)) | Multiple selections needed; single-document rule violated; EPO found same art novel | Selection irrelevant once compound is "covered" by genus claims | Upheld — coverage equals disclosure; specific disclosure immaterial |
| Inventive Step (S. 2(1)(ja)) | Order cryptic; no motivation-to-combine analysis | Follows automatically once novelty lost; "person in the know" standard applies | Not decided — rendered moot |
| Section 3(d) | Known substance never identified; PK data shows efficacy | PK data shows performance, not efficacy; foreign grants irrelevant | Upheld — bioavailability ≠ therapeutic efficacy |
| Co-inventor's affidavit | Non-consideration violates natural justice | — | Examined by Court itself; found insufficient; treated as cured |
Disposition
The impugned order dated 27 April 2023 was upheld in its entirety on lack of novelty and non-patentability under Section 3(d); the appeal was dismissed, with no order as to costs.